SCHEMBL174992

SCHEMBL174992

Cc1cc(Nc2nc(C(C)(NC(=O)O)c3ccc(F)cc3)nc3ccccc23)n[nH]1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.58
CYP3A4 P08684 3/20 0.58
CYP2C8 P10632 3/20 0.58
CYP2C9 P11712 3/20 0.58
JAK1 P23458 3/20 0.58
TYK2 P29597 3/20 0.58
CYP2C19 P33261 3/20 0.58
JAK3 P52333 3/20 0.58
ADORA3 P0DMS8 2/20 0.58
CYP1A2 P05177 1/20 0.58
NTRK1 P04629 6/20 0.57
AURKA O14965 10/20 0.57
AURKB Q96GD4 7/20 0.57
SRC P12931 5/20 0.56
GSK3B P49841 5/20 0.56
EIF2AK2 P19525 1/20 0.56
GSK3A P49840 1/20 0.56
NTRK3 Q16288 1/20 0.52
NTRK2 Q16620 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15258914 0.87 JAK2 (0.61) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL173929 0.87 AURKA (0.53) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL174552 0.86 JAK2 (0.62) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL168759 0.85 NTRK1 (0.66) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL721188 0.78 CCNE2 (0.39) CYP3A4CYP2C19CYP1A2
SCHEMBL173501 0.78 AURKA (0.88) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL158164 0.76 AURKA (0.57) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL165657 0.75 JAK2 (0.56) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL175070 0.75 AURKA (0.63) JAK2CYP3A4CYP2C8CYP2C9JAK1
SCHEMBL3787760 0.74 JAK2 (0.75) JAK2CYP3A4CYP2C8CYP2C9JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349851-B2 JAK kinase modulating compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2013-01-08 US disclosed
US-20120053176-A1 ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. (US) 2012-03-01 US disclosed
EP-2401267-A1 JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2012-01-04 EP disclosed
US-20100317659-A1 JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP. 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317659-A1 JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF JAK2, JAK3, JAK1 JAK2 1/4885CYP3A4 3115/4885CYP2C8 2046/4885
US-20120053176-A1 ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF ADORA2A, ADORA3, ADORA1 JAK2 3914/4885CYP3A4 2890/4885CYP2C8 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.